The impact of the RTS,S malaria vaccine on uncomplicated malaria: evidence from the phase IV study districts, Upper East Region, Ghana, 2020–2022

Malaria Journal, Journal Year: 2024, Volume and Issue: 23(1)

Published: Oct. 10, 2024

The RTS,S malaria vaccine has been prequalified for use in endemic settings prioritizing areas with moderate to high disease transmission. impact of a at the population level may differ from observations during clinical trial due programmatic, and individual-related factors, among others. objective this study was assess on uncomplicated children aged 12-59 months Phase IV districts, Upper East Region, Ghana.

Language: Английский

---

RTS, S malaria vaccination among children aged 24–59 months in the Sunyani Municipality, Ghana; 2023

Vaccine, Journal Year: 2024, Volume and Issue: 42(26), P. 126490 - 126490

Published: Nov. 1, 2024

Following the successful pilot of RTS,S malaria vaccine, it has been recommended by WHO for prevention Plasmodium falciparum in children living endemic areas. Despite proven benefits uptake especially fourth dose, remains relatively low. We assessed complete vaccine among 24-59 months and associated factors Sunyani Municipality Ghana.

Language: Английский

---

Performance characteristics and potential public health impact of improved pre-erythrocytic malaria vaccines targeting childhood burden

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 12, 2024

Abstract New malaria vaccine development builds on groundbreaking recommendations and roll-out of two approved pre-erythrocytic vaccines (PEVs); RTS,S/AS01 R21/MM. Whilst these are effective in reducing childhood within yearly routine immunization programs or seasonal vaccination, there is little evidence how different PEV efficacies, durations protection, spacing between doses influence the potential to avert uncomplicated severe malaria. Mainly, lacking understanding required properties delivery strategies that lead an with multi-year protection. We used individual-based model transmission informed by trial data quantify trade-offs performance impact across endemicities, deployment schedules, coverage levels. found deploying a 90% initial efficacy, six 12-month half-life duration co-administered blood-stage drug, followed boosters, results 60-80% incidence reduction, consistent RTS,S R21 trials. Halting vaccination after five years, leads sustained protection at least 35% reduction children <six years 12 months following cessation settings where Pf PR 2-10 <30%. Increasing -18 reaching more provides same health lower efficacy. Without booster (fourth dose), high efficacy (>90%) longer (>12 months) sustain beyond primary averting up half preceding year’s burden. The contribution each property overall varies setting clinical endpoint, indicating public goals should dictate key criteria. Overall, our findings support need for well-defined target product profiles long linking priority use cases where, how, whom deploy new vaccines, maximize impact.

Language: Английский

---

Barriers to uptake of RTS, S malaria vaccine in a malaria endemic area of western Kenya

Research Square (Research Square), Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 1, 2024

Background: Globally in 2021, there were an estimated 247 million malaria cases 85 malaria-endemic countries which accounted for over 619,000 deaths worldwide. An 27 and 12,600 attributed to Kenya the year 2020 (1). In every 1000 live births, 84 die before attaining 5 years Kenya(12). Despite implementation of several prevention measures, infection is still high with children under age being most vulnerable. As a complimentary existing measured, vaccine age. However, low uptake, especially 3^rd 4^th doses limited information on reasons uptake. This study aimed at identifying uptake RTS, S Muhoroni sub-county Kenya. Methods: Study design: The employed exploratory design. A purposeful sampling method was used select participants focus group discussions (FGDs) key informant interviews (KIIs). Four FGDs conducted, 3 them involved 25 parent/guardian whose either completed or didn’t complete recommended 4 receive all, 1 FGD 11 community health volunteers (CHVs). KII nurses charge maternal child (MCH) clinics. KIIs guides data collection. Data analyzed thematically using NVIVO version 12. Results: gaps are inadequate knowledge about both parents/guardians nurses, side effects number doses. Others poor attitude care providers, unavailability, understaffing providers resulting long waiting times, migration non-implementing sub-counties. Conclusion: Barriers were: Inadequate vaccine, doses, migrations, queue due staff understaffing, economic activities, cultural beliefs trainings nurses.

Language: Английский

---

Malaria, its Prevention and Control: Perspectives from the Social Sciences

Springer eBooks, Journal Year: 2023, Volume and Issue: unknown, P. 1 - 20

Published: Jan. 1, 2023

Language: Английский

---